

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Not for submission under 37 CFR 1.99)	Application Number		10821718	
	Filing Date		2004-04-09	
	First Named Inventor	Clyde L. Schultz		
	Art Unit	1615		
	Examiner Name	Sarah Alawadi		
Attorney Docket Number		RH01.701US		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	4668506		1987-05-26	Bawa	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20080318843		2008-12-25	Schultz et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	03092665	WO		2003-11-13	Carrasquillo et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS			Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10821718
Filing Date	2004-04-09
First Named Inventor	Clyde L. Schultz
Art Unit	1615
Examiner Name	Sarah Alawadi
Attorney Docket Number	RH01.701US

1	COLTHURST ET AL., Biomaterials used in the posterior segment of the eye, Elsevier Science Ltd., Biomaterials, 2000, pp 649-665.	<input type="checkbox"/>
2	ZHANG ET AL., Angiogenic Inhibition Mediated by a DNazyme That Targets Vascular Endothelial Growth Factor Receptor 2, Cancer Research 62, October 1, 2002, 7 pages.	<input type="checkbox"/>
3	U.S. Office Action issued March 20, 2009 issued in U.S. Application No. 11/102,454, 27 pages.	<input type="checkbox"/>
4	U.S. Office Action issued June 10, 2009 issued in U.S. Application No. 10/971,997, 7 pages.	<input type="checkbox"/>
5	U.S. Office Action issued November 4, 2009 issued in U.S. Application No. 11/102,454, 213 pages.	<input type="checkbox"/>
6	U.S. Office Action issued December 24, 2009 issued in U.S. Application No. 10/971,997, 10 pages.	<input type="checkbox"/>
7	AIELLO ET AL., Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins, Proc. Natl. Acad. Sci. USA, November 1995, pp. 10457-10461, Vol. 92.	<input type="checkbox"/>
8	CLARK ET AL., A Vascular Endothelial Growth Factor Antagonist Is Produced by the Human Placenta and Released into the Maternal Circulation, Biology of Reproduction, 1998, pp 1540-1548, Vol. 59.	<input type="checkbox"/>
9	DUH ET AL., Vascular Endothelial Growth Factor and Diabetes - The Agonist Versus Antagonist Paradox, Diabetes - Perspectives in Diabetes, 8 pages, October 1999, Vol. 48.	<input type="checkbox"/>
10	FLIEGER ET AL., Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab, Ann Hematol - Letter to the Editor, 2006, pp 631-632, Vol. 85.	<input type="checkbox"/>
11	HAZZARD ET AL., Injection of Soluble Vascular Endothelial Growth Factor Receptor 1 into the Preovulatory Follicle Disrupts Ovulation and Subsequent Luteal Function in Rhesus Monkeys, Biology of Reproduction, 2002, pp 1305-1312, Vol. 67.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10821718
Filing Date	2004-04-09
First Named Inventor	Clyde L. Schultz
Art Unit	1615
Examiner Name	Sarah Alawadi
Attorney Docket Number	RH01.701US

12	HETIAN ET AL., A Novel Peptide Isolated from a Phage Display Library Inhibits Tumor Growth and Metastasis by Blocking the Binding of Vascular Endothelial Growth Factor to Its Kinase Domain Receptor, The Journal of Biological Chemistry, November 8, 2002, pp. 43137-43142, Vol. 277, No. 45.	<input type="checkbox"/>
13	INOUE ET AL., Identification of a vascular endothelial growth factor (VEGF) antagonist, sFlt-1, from a human hematopoietic cell line NALM-16, Federation of European Biochemical Societies, Letters, 2000, pp 14 18, Vol 469.	<input type="checkbox"/>
14	KIMURA ET AL., Vascular Endothelial Growth Factor Antagonist Reduces Brain Edema Formation and Venous Infarction, Journal of the American Heart Association - Stroke, May 5, 2005, pp 1259-1263, Vol. 36.	<input type="checkbox"/>
15	OZAKI ET AL., Blockade of Vascular Endothelial Cell Growth Factor Receptor Signaling Is Sufficient to Completely Prevent Retinal Neovascularization, American Journal of Pathology, February 2000, 11, pages, Vol. 156, No. 2.	<input type="checkbox"/>
16	PISANO ET AL., Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist, Glycobiology, 2005, pp 1C-6C, Vol. 15, No. 2	<input type="checkbox"/>
17	SCHUCH ET AL., In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo, NeoPlasia, Blood, December 15, 2002, 7 pages, Vol. 100, No. 13.	<input type="checkbox"/>
18	SIEMEISTER ET AL., An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells, Proc. National Academy of Sciences USA, April 1998, pp 4625-4629, Vol. 95.	<input type="checkbox"/>
19	SOKER ET AL., Inhibition of Vascular Endothelial Growth Factor (VEGF)-induced Endothelial Cell, Proliferation by a Peptide Corresponding to the Exon 7-Encoded Domain of VEGF-165, The Journal of Biological Chemistry, December 12, 1997, pp 31582-31588, Vol. 272 No. 50.	<input type="checkbox"/>
20	DEL AMO ET AL., Current and future ophthalmic drug delivery systems - A shift to the posterior segment, Drug Discovery Today, February 2008, 9 pages, Vol. 12, Numbers 3/4.	<input type="checkbox"/>
21	FATTAL ET AL., Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA, Science Direct, Advanced Drug Delivery Reviews, 2006, pp 1203-1223, Vol. 58.	<input type="checkbox"/>
22	MYLES ET AL., Recent progress in ocular drug delivery for posterior segment disease; Emphasis on transscleral iontophoresis, Science Direct, Advanced Drug Delivery Reviews, 2005, pp 2063-2079, Vol 57.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10821718
Filing Date	2004-04-09
First Named Inventor	Clyde L. Schultz
Art Unit	1615
Examiner Name	Sarah Alawadi
Attorney Docket Number	RH01.701US

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Sarah Alawadi/	Date Considered	07/03/2010
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.